Your browser doesn't support javascript.
loading
Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.
Sugiura, Masahiro; Sato, Hiroaki; Okabe, Atsushi; Fukuyo, Masaki; Mano, Yasunobu; Shinohara, Ken-Ichi; Rahmutulla, Bahityar; Higuchi, Kosuke; Maimaiti, Maihulan; Kanesaka, Manato; Imamura, Yusuke; Furihata, Tomomi; Sakamoto, Shinichi; Komiya, Akira; Anzai, Naohiko; Kanai, Yoshikatsu; Luo, Jun; Ichikawa, Tomohiko; Kaneda, Atsushi.
Afiliación
  • Sugiura M; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Sato H; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Okabe A; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Fukuyo M; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Mano Y; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Shinohara KI; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Rahmutulla B; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Higuchi K; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Pharmacology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Maimaiti M; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kanesaka M; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan.
  • Imamura Y; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Furihata T; Department of Pharmacology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Sakamoto S; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Komiya A; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Anzai N; Department of Pharmacology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kanai Y; Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Osaka, Japan.
  • Luo J; Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University, Baltimore, MD, USA.
  • Ichikawa T; Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.
  • Kaneda A; Department of Molecular Oncology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chuo-ku, Chiba, Japan. Electronic address: kaneda@chiba-u.jp.
Transl Oncol ; 14(1): 100915, 2021 Jan.
Article en En | MEDLINE | ID: mdl-33096335
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Diagnostic_studies Idioma: En Revista: Transl Oncol Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos